Search

Displaying results 3091 - 3100 of 7603 in total
  1. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

  2. Drug

    Gadofosveset trisodium

    go.drugbank.com/drugs/DB06705
    Approved

    The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully

  4. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

  5. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  6. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

  7. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  8. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin.

    Categories: Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives.

  10. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.